| Name | Title | Contact Details |
|---|---|---|
Karen Gibson |
Chief Technology Officer | Profile |
Karen Gibson |
Senior Vice President of Information Technology and Chief Information Officer | Profile |
Capital City Nurses is a Chevy Chase, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BabelBark is the most comprehensive pet health management tool available, managing pets care, records and fitness all in one place. The BabelBark mobile app for pet parents links with the software platforms for pet businesses, shelters and veterinarians to help pets live the happiest, healthiest lives possible—by connecting everyone who cares for them! Whether you love, treat, groom, train, walk or sit for pets—BabelBark helps you do it even better.
Kingston Health Care Company is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Kingston Health Care Company is based in Toledo, OH. You can find more information on Kingston Health Care Company at www.kingstonhealthcare.com
Equality Health, LLC is a Phoenix-based whole-health delivery system focused on transforming value-based care delivery with population-specific programs that improve access, quality, and member trust. Through an integrated technology and services platform, culturally competent provider network and personalized care model, Equality Health helps managed care plans and health systems improve outcomes for diverse populations while simultaneously making the transition to risk-based accountability.
OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.